Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer.
Kevin P O'RourkeEvangelia LoizouGeulah LivshitsEmma M SchatoffTimour BaslanEusebio ManchadoJanelle SimonPaul B RomesserBenjamin LeachTeng HanChantal PauliHimisha BeltranMark A RubinLukas E DowScott W LowePublished in: Nature biotechnology (2017)
Colorectal cancer (CRC) is a leading cause of death in the developed world, yet facile preclinical models that mimic the natural stages of CRC progression are lacking. Through the orthotopic engraftment of colon organoids we describe a broadly usable immunocompetent CRC model that recapitulates the entire adenoma-adenocarcinoma-metastasis axis in vivo. The engraftment procedure takes less than 5 minutes, shows efficient tumor engraftment in two-thirds of mice, and can be achieved using organoids derived from genetically engineered mouse models (GEMMs), wild-type organoids engineered ex vivo, or from patient-derived human CRC organoids. In this model, we describe the genotype and time-dependent progression of CRCs from adenocarcinoma (6 weeks), to local disseminated disease (11-12 weeks), and spontaneous metastasis (>20 weeks). Further, we use the system to show that loss of dysregulated Wnt signaling is critical for the progression of disseminated CRCs. Thus, our approach provides a fast and flexible means to produce tailored CRC mouse models for genetic studies and pre-clinical investigation.
Keyphrases
- induced pluripotent stem cells
- mouse model
- wild type
- squamous cell carcinoma
- small cell lung cancer
- gestational age
- endothelial cells
- hematopoietic stem cell
- cell therapy
- locally advanced
- gene expression
- minimally invasive
- dna methylation
- copy number
- stem cells
- radiation therapy
- adipose tissue
- skeletal muscle
- metabolic syndrome
- smoking cessation
- high fat diet induced
- pluripotent stem cells